3/23/2023 0 Comments Texas retina associatesGibney was Executive Vice President and Chief Business Officer at Achillion Pharmaceuticals, where he led the successful sale of Achillion to Alexion Pharmaceuticals in 2020. Gibney served as Chief Financial Officer and Chief Business Officer at Fog Pharmaceuticals overseeing the business development, strategy and finance functions of the company. Gibney is an experienced biotechnology executive and former investment banker with over 25 years of experience dedicated to advising biotechnology companies. Tony Gibney is Executive Vice President and Chief Business and Strategy Officer of Iveric Bio. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. He then attended UCLA School of Medicine, then residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. He was also captain of the Columbia Squash team. He graduated Summa cum Laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness.ĭr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. Dugel has been a member of the board of directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. He has consulted for over 50 companies and has served on the Aerpio Therapeutics board of directors.ĭr. Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame.ĭr Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. He is on the editorial board of several major medical journals. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California and Founding Member, Spectra Eye Institute in Sun City, Arizona.ĭr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.ĭr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. in a variety of senior financial positions. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |